---
id: bacteriophage-therapy-clinical_252
category: antimicrobials
tags: [bacteriophage, phage-therapy, FDA, clinical-trials, compassionate-use]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Bacteriophage Therapy: Clinical Use and FDA Regulation

**Q:** What is the current regulatory status of bacteriophage therapy in the United States, and what clinical evidence supports its use?

**A:**

**FDA Status:**
- **No approved products** for human therapeutic use
- Available only via **Emergency IND/Compassionate Use** (30-day FDA review)
- Requirements: Clinical need, in vitro susceptibility, genetic characterization, sterility (USP 71), minimal endotoxin, **no lysogenic activity**
- >99% of expanded-access applications approved

**Clinical Evidence:**
- ~**90 trials worldwide** (41 in US) - Phase 1/2a
- **70% lower bacterial eradication** with phage monotherapy vs. phage + antibiotics
- Active targets: *P. aeruginosa* (VAP, CF), MDR *E. coli* (UTI), diabetic foot ulcers, bacteremia
- Notable programs: TAILÎ¦R (Baylor), ELIMINATE trial (Locus Biosciences), CF-301/Exebacase (endolysin - Phase III)

*Pearl:* Combination with antibiotics superior to monotherapy.

**Media:**

**Sources:** [PMC12389134], [FDA CBER Guidance 2022], [STAT News Phage Therapy 2024]
